Requirement for MUC5AC in KRAS-dependent lung carcinogenesis

Area of Science:

• Oncology
• Molecular Biology
• Cancer Genetics

Background:

• Lung cancer, particularly non-small cell lung carcinoma (NSCLC), causes over 150,000 deaths annually in the US.
• Lung adenocarcinoma (ADC), the most common NSCLC subtype, is driven by KRAS and EGFR mutations.
• Effective KRAS inhibition is lacking, despite some success with EGFR blockade, highlighting an unmet clinical need.

Purpose of the Study:

• To investigate the causal role of the gel-forming mucin MUC5AC in KRAS-driven lung adenocarcinoma (ADC).
• To determine if MUC5AC expression correlates with prognosis in lung ADC patients, especially those with KRAS mutations.

Main Methods:

• Analysis of MUC5AC expression and its correlation with patient prognosis in lung ADC cohorts.
• Utilized mouse models of lung ADC induced chemically (urethane) and transgenically (mutant-Kras).
• Compared tumor development in wild-type mice versus mice lacking Muc5ac.

Main Results:

• MUC5AC expression was a significant determinant of poor prognosis, particularly in KRAS-mutant lung ADC.
• Mice lacking Muc5ac exhibited significantly reduced tumor development in both urethane-induced and Kras-mutant lung ADC models.
• These findings establish a causative link between Muc5ac and KRAS-driven lung ADC progression.

Conclusions:

• MUC5AC plays a crucial role in the development and progression of KRAS-mutant lung adenocarcinoma.
• MUC5AC represents a promising therapeutic target for lung ADC, a disease with limited treatment options.
• Targeting MUC5AC could offer a novel strategy to improve outcomes for patients with KRAS-mutant lung cancer.